Patrick Rood
Physician Assistant · Amherst, NYNPI 1679681985
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 856 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,604 and has fallen 93.8% since, to $284 in 2025. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 856 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$1K
- MDD US Operations, LLC$1K
- Novartis$1K
- AbbVie$1K
- Amgen$1K
- Teva Pharmaceuticals USA, Inc.$801
- plus $7K from 47 others
What the payments were for
- Consulting fees$1501%
- Food & beverage$13,80598%
- Education$1901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,145 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 20 | $291,194 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 71 | $249,107 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 22 | $209,326 |
| GilenyaFingolimod Hcl | 17 | $163,325 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 18 | $144,015 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $122,970 |
| FingolimodFingolimod Hcl | 19 | $67,120 |
| Dimethyl Fumarate | 11 | $47,631 |
| Glatiramer Acetate | 13 | $39,938 |
| Rasagiline Mesylate | 72 | $15,802 |
| Gabapentin | 302 | $6,557 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 151 | $6,010 |
| Pregabalin | 125 | $4,508 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 11 | $4,496 |
| Pyridostigmine Bromide | 71 | $4,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $21 | $249,10771 claims |
| PfizerOctagam | $297 | $209,32622 claims |
| NovartisGilenya | $1,096 | $163,32517 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $20 | $122,97013 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil | $354 | $6,09188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Amherst
- Michael AsbachAmherst$962K
- Madeline SliszAmherst$101K
- Rachel AllenAmherst$54K
- Lauren JendraszekAmherst$40K
- Delaney FragaleAmherst$33K
- Henry YuBronx$1M
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
- Melissa WhiteGarden City$320K
- Lawrence HermanHolbrook$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.